Eye drop showdown: could common glaucoma meds save more than sight?

NCT ID NCT07074782

Not yet recruiting Knowledge-focused Sponsor: Association for Innovation and Biomedical Research on Light and Image Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a common type of glaucoma eye drop (prostaglandin analogues) can protect the eye's nerve cells directly, not just by lowering eye pressure. Researchers will review medical records from 1500 adults with glaucoma over 3 years, comparing those on prostaglandin drops to those on other pressure-lowering drops. The goal is to see if one type offers better long-term nerve protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exfoliation syndrome glaucoma low tension glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Locations

Centre for Clinical Trials at San Paolo Hospital University of Milan

Milan, Italy
Centro de Oftalmologia Barraquer

Barcelona, Spain
Clinical Eye Research Centre - St. Paul's Eye Unit, Royal Liverpool University Hospital

Liverpool, United Kingdom
Department of Ophthalmology University of Bonn

Bonn, Germany
Eye Unit, University Hospital Maggiore della Carità

Novara, Italy
ICORG - Imperial College Ophthalmologic Research Group

London, United Kingdom
NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust

London, United Kingdom
Retina Unit, Department of Ophthalmology, Bellvitge University Hospital

Barcelona, Spain
University Eye Hospital Leipzig

Leipzig, Germany
University Hospital Basel

Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.